Peer Exchange

AJMC® Peer Exchange® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.

EP. 1: An Overview of the Epidemiology of SMA

EP. 2: Clinical Burden of Spinal Muscular Atrophy

EP. 1: Overview of Myeloproliferative Neoplasms (MPNs)

EP. 2: Diagnosis of MPNs

EP. 3: Approaching MPN Patient Treatment

EP. 4: Building the Best Oncology Care Process for MPNs

EP. 5: Heterogeneity of Therapy in Patients With MPNs

EP. 6: Practice Guidelines and the Decision-Making Process for MPNs

EP. 7: The Application of Guideline Adherence Around MPNs

EP. 8: Integrating New Practice Guidelines and Processes for MPNs

EP. 9: Impact of Telehealth on MPNs During COVID-19

EP. 10: Using Technology to Increase Patient Adherence in MPNs

EP. 11: Individual Treatment Plans for MPN Patients

EP. 12: Stem Cell Transplantation Intervention for MF

EP. 13: Enhancing Patient Adherence in MPN

EP. 14: Overcoming Barriers to Treatment Adherence in MPN

EP. 15: Patient Compliance: Role of Pharmacists on MPN Care Teams

EP. 16: Management of MPN: Benchmarks For Quality Care

EP. 1: R/R Multiple Myeloma Rationale for Decreased Response

EP. 2: Importance of MRD Negativity in Changing Relapse Patterns

EP. 3: Treating Biochemical Relapses in Multiple Myeloma

EP. 4: Upfront Daratumumab Impact on Relapse Treatment

EP. 5: CANDOR Trial Overview and Regimen Complications

EP. 6: Clinical Significance of DKd Dosing Flexibility

EP. 7: Therapy Selection for Newly Diagnosed Multiple Myeloma

EP. 8: ASH 2020 Data: DKd Versus DVd Implications

EP. 9: Impact of the Phase 3 APOLLO Trial Recent Findings

EP. 10: Implications of the IKEMA Interim Analysis

EP. 11: The Role of Venetoclax in R/R Multiple Myeloma

EP. 12: The Future of R/R Multiple Myeloma Management

EP. 1: Acute and Preventive Treatment: Differences and QOL Impact

EP. 2: Acute Migraine Treatment: Prevalence and Classes of Agents

EP. 3: Acute Migraine Therapy Unmet Needs

EP. 4: Drivers of Health Care Utilization for Uncontrolled Migraine

EP. 5: Advancements in Migraine Diagnosis and Treatment

EP. 6: Determining and Measuring Individualized Treatment Goals

EP. 7: Transitioning from Acute to Preventive Care

EP. 8: Historical Perspective on Preventive Care

EP. 9: New CGRP Monoclonal Antibodies for Preventive Care

EP. 10: CGRP Monoclonal Antibodies: AEs and Efficacy

EP. 11: Patient-Reported Outcomes Data on Adverse Events

EP. 12: Migraine Therapy Selection and Duration

EP. 13: Measuring Response in Goal-Based Therapy

EP. 14: Combining Acute and Preventive Therapy

EP. 15: Managing Migraine Patients During the Pandemic

EP. 1: Overview of CAR T-cell Therapy in R/R NHL

EP. 2: Transplant-Eligibility and CAR T Considerations in R/R NHL

EP. 3: ZUMA-1 Trial Using CAR T in R/R NHL

EP. 4: Optimizing CAR T in R/R NHL

EP. 5: Emerging Therapies and Future of CAR T-Cell Therapy

EP. 6: Patient Selection of CAR T-Cell Therapy in R/R NHL

EP. 7: Barriers to CAR T Therapy for R/R NHL

EP. 8: Value of Outpatient CAR T Administration in R/R NHL

EP. 9: Requirements for CAR T in a Community Setting

EP. 10: Outpatient CAR T in R/R NHL: Policies and Procedures

EP. 11: Role of CAR T Administration in the Community

EP. 12: Educating Providers for Outpatient CAR T Administration

EP. 13: Importance of Monitoring Patient AEs With Outpatient CAR T

EP. 14: Management of Outpatient CAR T Adverse Events

EP. 15: Evolving Treatment Paradigm of R/R NHL and Outpatient CAR T

EP. 16: Future of Outpatient CAR T Administration

EP. 1: Choosing Drug-related Routes of Administration

EP. 2: Routes of Administration: Adherence and Persistence

EP. 3: Alignment of Incentives: Optimizing Routes of Administration

EP. 4: Cost Considerations for Self- vs HCP-administered Agents

EP. 5: Preferred Site of Care and Coverage for Infusions

EP. 6: Utilization Management Through Medical and Pharmacy Benefit

EP. 7: Cost Dispersion of Infused Drugs

EP. 8: Self-injectables: Emerging Agents for the Management of MS

EP. 9: Evolving Management of Drug Spending Monitoring

EP. 10: Transparency Among Medical and Pharmacy Benefits

EP. 11: Management of Drug Spending and Impact of COVID-19

EP. 12: Future of Medical and Pharmacy Benefit Integration